Singapore, May 29 -- Samsung Epis Holdings Co., an investment holding company dedicated to innovation in biopharmaceuticals and biotechnology, has announced the establishment of a new research and development (R&D) centre in Changping District, Beijing, China, marking a significant milestone in the company's evolution as an investment holding company.

"The establishment of the new R&D centre reflects our commitment to advancing new growth opportunities and strengthening our competitiveness in novel drug development," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. "By bringing together world-class scientific talent and advanced technological infrastructure in China, which has become an increasingl...